683 Capital Management, LLC Leap Therapeutics, Inc. Transaction History

683 Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.29 - $0.72 $14,499 - $36,000	50,000 Added 1.82%	2,800,000 $952,000
Q4 2022 Feb 14, 2023	BUY	$0.42 - $9.18 $203,700 - $4.45 Million	485,000 Added 21.41%	2,750,000 $1.24 Million
Q3 2022 Nov 14, 2022	BUY	$0.92 - $9.3 $759,164 - $7.67 Million	825,179 Added 57.31%	2,265,000 $1.99 Million
Q2 2022 Aug 15, 2022	BUY	$0.96 - $1.91 $507,884 - $1.01 Million	529,046 Added 58.09%	1,439,821 $1.66 Million
Q1 2022 May 16, 2022	BUY	$1.6 - $3.35 $1.46 Million - $3.05 Million	910,775 New	910,775 $1.59 Million
Q1 2021 May 17, 2021	SELL	$1.82 - $3.01 $365,394 - $604,305	-200,766 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $485,293 - $771,909	-325,700 Reduced 61.87%	200,766 $452,000
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $347,500 - $710,000	250,000 Added 90.43%	526,466 $1.1 Million
Q1 2020 May 15, 2020	BUY	$1.06 - $2.94 $133,903 - $371,392	126,324 Added 84.14%	276,466 $437,000
Q1 2019 May 15, 2019	BUY	$1.39 - $3.07 $197 - $435	142 Added 0.09%	150,142 $281,000
Q1 2018 May 15, 2018	BUY	$6.06 - $8.54 $908,999 - $1.28 Million	150,000 New	150,000 $1.25 Million

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.